Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... October 31, 2014 Jeffrey T. Manuel, ... Historical Studies within the College of Arts and Sciences, ... record the history of alcohol-based fuels in Illinois. ... others have been working to build Illinois’ biofuels industry ... overlooked aspect of the state's agricultural and business history. ...
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/30/2014)... 2014 Investor-Edge has initiated coverage ... ONVO), Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics ... (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). ... at: http://investor-edge.com/register . On Wednesday, October ... 0.33%, the Dow Jones Industrial Average declined 0.18%, to ...
(Date:10/30/2014)... 30, 2014 SoundConnect , ... offers Office 365 end users the key to ... phone system by adding voice enablement and hybrid ... Lync Online, a communication tool that includes presence, ... hosted voice, O365 becomes a comprehensive unified communications ...
Breaking Biology Technology:SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3
... Calif., Feb. 4 Arryx, Inc.,announced the addition ... Holographic Optical Trapping ("HOT") product line. The HOTkit,Complete ... events, and now, through the power of light, ... The HOTkit Complete was unveiled February 4 ...
... HORSHAM, Pa., Feb. 4 Centocor, Inc. announced ... (CNTO 1275),has been accepted for review by the ... of adult patients with chronic moderate to severe ... with a novel,mechanism of action that targets the ...
... HAVEN, Conn., Feb. 4 VION,PHARMACEUTICALS, INC. (Nasdaq: ... the Company,s senior management team as Vice President,Medical., ... pleased,to have Bill Hahne joining Vion in medical affairs. ... will be extremely useful to our,efforts to file a ...
Cached Biology Technology:Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 2Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 3Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 2Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 3
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
(Date:10/29/2014)... and industrial products are in the environment – and ... them, scientists have yet to determine whether they cause ... doing that by estimating which substances people are exposed ... the ACS journal Environmental Science & Technology . ... risks to human health of any given substance depend ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2MSU partners with Detroit to investigate death scenes 2
... of California, San Diego has discovered a molecule in ... or Bt toxin--a pesticide produced by bacteria and widely ... to ward off insect pests. , Their findings should ... prevent insects, which the researchers believe also possess the ...
... scientific world has accepted for more than 100 ... by their grandparents, bypassing genetic abnormalities carried by ... have hidden templates containing genetic information from the ... offspring, even though the traits aren't evident in ...
... to coax mouse stem cells to transform themselves into fat ... naturally do in the body. , While other studies have ... cells never completely functioned in the same way they do ... biologic components that all cells require to do their work. ...
Cached Biology News:UCSD discovery may help extend life of natural pesticide 2UCSD discovery may help extend life of natural pesticide 3Plants defy Mendel's inheritance laws, may prompt textbook changes 2Plants defy Mendel's inheritance laws, may prompt textbook changes 3Tiny scaffolding allows stem cells to become working fat cells 2Tiny scaffolding allows stem cells to become working fat cells 3
...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
... utilizes a silica based spin filter membrane to ... desired DNA band is cut from an agarose ... unit. The gel slice is melted irreversibly in ... is bound to the silica spin filter membrane ...
Biology Products: